6,465 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by Commerce Bank

Commerce Bank acquired a new stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,465 shares of the company’s stock, valued at approximately $207,000.

Other large investors have also bought and sold shares of the company. D. E. Shaw & Co. Inc. boosted its stake in SpringWorks Therapeutics by 16.9% in the second quarter. D. E. Shaw & Co. Inc. now owns 758,712 shares of the company’s stock valued at $28,581,000 after buying an additional 109,865 shares in the last quarter. Seven Eight Capital LP acquired a new stake in SpringWorks Therapeutics in the second quarter valued at about $1,854,000. Los Angeles Capital Management LLC boosted its stake in SpringWorks Therapeutics by 238.3% in the third quarter. Los Angeles Capital Management LLC now owns 47,212 shares of the company’s stock valued at $1,513,000 after buying an additional 33,255 shares in the last quarter. Victory Capital Management Inc. boosted its stake in SpringWorks Therapeutics by 3.7% in the second quarter. Victory Capital Management Inc. now owns 525,983 shares of the company’s stock valued at $19,814,000 after buying an additional 18,652 shares in the last quarter. Finally, Mutual of America Capital Management LLC boosted its stake in SpringWorks Therapeutics by 41.4% in the second quarter. Mutual of America Capital Management LLC now owns 116,915 shares of the company’s stock valued at $4,404,000 after buying an additional 34,260 shares in the last quarter.

Wall Street Analyst Weigh In

SWTX has been the topic of several research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $77.00 price objective on shares of SpringWorks Therapeutics in a research note on Monday, November 18th. HC Wainwright cut their price target on SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a research note on Tuesday, November 12th. Evercore ISI started coverage on SpringWorks Therapeutics in a research note on Wednesday, November 20th. They set an “outperform” rating and a $60.00 price target on the stock. Finally, JPMorgan Chase & Co. lifted their price target on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $67.00.

SpringWorks Therapeutics Price Performance

SpringWorks Therapeutics stock opened at $41.73 on Thursday. The stock’s 50 day moving average is $32.92 and its 200 day moving average is $36.75. The firm has a market cap of $3.10 billion, a P/E ratio of -10.76 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a one year low of $23.00 and a one year high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.03. The company had revenue of $49.10 million for the quarter, compared to analyst estimates of $53.28 million. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. The firm’s quarterly revenue was up 4810.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.27) earnings per share. Equities analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.12 earnings per share for the current fiscal year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.